Tango Therapeutics Inc (TNGX NASDAQ) stock market data APIs
$9.3108
-0.17(-1.8%)
as of December 12, 2025
Try our APIs with
free plan!
Tango Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Prev. Close
9.3108
Open
9.1419
High
9.619
Low
9.0502
52 wk Range
1.03-11.2
Market Cap
1 259 M
Shares Outstanding
135 M
Revenue
66 501 K
EPS
-0.14
Beta
1.724
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tango Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tango Therapeutics Inc data using free add-ons & libraries
Get Tango Therapeutics Inc Fundamental Data
Tango Therapeutics Inc Fundamental data includes:
- Net Revenue: 66 501 K
- EBITDA: -107 913 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: -0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tango Therapeutics Inc News
New
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is sched...
Novavax, UniFirst, and More Stocks See Action From Activist Investors
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Continue Reading View Comments
Tango Therapeutics launches $100M at-the-market stock offering
* Tango Therapeutics (TNGX [https://seekingalpha.com/symbol/TNGX]) entered [https://seekingalpha.com/filing/52044862] a sales agreement with Leerink Partners to sell up to $100M of common stock thro...
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?
Key Points Venture capital fund Third Rock Ventures IV, L.P. sold 477,401 shares of Tango Therapeutics on October 23, 2025. Third Rock Ventures IV, L.P. is a 10% owner in Tango Therapeutics.These 10 ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
